Hypertensive Disorders in Pregnancy: A Comprehensive Clinical Review

Abstract

Hypertensive disorders remain a leading contributor to maternal and perinatal morbidity and mortality worldwide. This review synthesizes recent evidence and guidelines regarding the classification, pathophysiology, clinical manifestations, risk factors, diagnostic approaches, and management of hypertensive disorders in pregnancy. Emphasis is placed on practical implications for clinical care, emerging therapies, and future research priorities, aiming to equip healthcare professionals with up-to-date, mechanism-based, and patient-centered knowledge for optimal maternal and fetal outcomes.

Introduction

Hypertensive disorders in pregnancy (HDP) encompass a spectrum including chronic hypertension, gestational hypertension, preeclampsia, eclampsia, and preeclampsia superimposed on chronic hypertension. Affecting approximately 5–10% of pregnancies globally, HDP represent a significant clinical challenge due to their association with adverse maternal, fetal, and neonatal outcomes. Recent advances in understanding the pathophysiology and evidence-based management have informed updated guidelines, yet the burden remains substantial, especially in low- and middle-income countries. This review integrates current concepts, clinical insights, and guideline recommendations to support clinicians in the management of HDP.

Epidemiology / Disease Burden

Globally, hypertensive disorders of pregnancy are among the top causes of maternal and perinatal mortality. The World Health Organization estimates that HDP contribute to 14% of maternal deaths. Incidence varies with demographic, geographic, and socioeconomic factors, with preeclampsia affecting 2–8% of pregnancies and eclampsia more prevalent in resource-limited settings. The disease burden is not restricted to the acute period; long-term sequelae include increased cardiovascular and renal risks for both mother and offspring. Disparities in access to antenatal care, diagnostic facilities, and emergency obstetric services further exacerbate outcomes in vulnerable populations.

Pathophysiology

The pathogenesis of HDP, particularly preeclampsia, is characterized by abnormal placentation leading to impaired trophoblast invasion and inadequate spiral artery remodeling. This results in placental ischemia and the release of antiangiogenic factors (such as sFlt-1 and endoglin) that disrupt endothelial function and promote systemic vasoconstriction. The subsequent maternal syndrome includes hypertension, proteinuria, and multi-organ dysfunction. Genetic predisposition, immune maladaptation, oxidative stress, and pre-existing vascular disease contribute to the heterogeneity and severity of presentations. Understanding these mechanisms has catalyzed biomarker discovery and targeted therapeutic strategies.

Risk Factors

Risk factors for HDP are multifactorial and encompass maternal, demographic, and pregnancy-specific elements. Advanced maternal age, obesity, nulliparity, multiple gestation, pre-existing hypertension, diabetes mellitus, chronic kidney disease, autoimmune disorders (e.g., antiphospholipid syndrome), and a personal or family history of preeclampsia significantly increase risk. Assisted reproductive technologies and certain sociodemographic backgrounds (e.g., Black ethnicity) are also associated with higher incidence. Early identification of high-risk individuals enables targeted surveillance and prophylactic interventions.

Clinical Features

HDP present with diverse clinical manifestations. Gestational hypertension is defined as new-onset hypertension (≥140/90 mmHg) after 20 weeks' gestation without proteinuria or end-organ dysfunction. Preeclampsia involves hypertension plus proteinuria (≥300 mg/24h) or, in its absence, features of systemic involvement such as renal insufficiency, hepatic dysfunction, neurological symptoms (headache, visual disturbances), thrombocytopenia, or pulmonary edema. Eclampsia is characterized by new-onset seizures in a woman with preeclampsia. Severe features may include systolic BP ≥160 mmHg, diastolic BP ≥110 mmHg, or evidence of multi-organ compromise. Clinical vigilance for atypical presentations is essential to prevent complications.

Diagnosis

Diagnosis of HDP relies on accurate blood pressure measurement, urinalysis for proteinuria (dipstick, protein-creatinine ratio, or 24-hour collection), and assessment for end-organ involvement. Laboratory evaluation includes renal and liver function tests, platelet count, and, if indicated, assessment of hemolysis and coagulation profiles. Imaging (e.g., fetal ultrasound, Doppler studies) aids in fetal surveillance. Emerging biomarkers (e.g., sFlt-1/PlGF ratio) show promise in risk stratification and prediction but have not yet supplanted traditional diagnostic criteria. Timely diagnosis is critical for initiating appropriate monitoring and intervention.

Treatment & Management

Management of HDP is guided by disease severity, gestational age, and maternal-fetal status. Antihypertensive therapy (labetalol, nifedipine, methyldopa) is recommended for sustained BP ≥160/110 mmHg. Magnesium sulfate remains the mainstay for seizure prophylaxis in preeclampsia with severe features or eclampsia. The only definitive cure for preeclampsia is delivery; timing must balance maternal stabilization against fetal maturity. Expectant management may be considered in select cases before 34 weeks with close monitoring. Corticosteroids are administered for fetal lung maturation if preterm delivery is anticipated. Multidisciplinary care, including anesthesia and neonatal support, is essential for optimal outcomes. Postpartum monitoring is crucial as complications can develop or persist after delivery.

Recent Advances / Emerging Therapies

Recent research has focused on the identification of biomarkers such as sFlt-1, PlGF, and angiogenic factors for earlier and more precise risk stratification. Trials are ongoing for targeted therapies, including statins, antiplatelet agents, and novel antiangiogenic interventions. Low-dose aspirin prophylaxis is now widely recommended for high-risk women based on robust evidence for reducing preeclampsia incidence. Advances in point-of-care diagnostics and telemedicine facilitate remote monitoring in resource-constrained settings. Genomic and proteomic insights offer opportunities for personalized medicine, though clinical application remains limited.

Guideline Recommendations

Current guidelines from organizations such as the American College of Obstetricians and Gynecologists (ACOG), National Institute for Health and Care Excellence (NICE), and International Society for the Study of Hypertension in Pregnancy (ISSHP) emphasize early identification of high-risk women, initiation of low-dose aspirin before 16 weeks' gestation, strict BP control, and individualized delivery planning. Magnesium sulfate is universally recommended for eclampsia prevention and treatment. Regular antenatal surveillance and postpartum follow-up are advocated to mitigate acute and long-term complications. Guideline adherence improves outcomes but requires adaptation to local resources and population needs.

Conclusion

Hypertensive disorders in pregnancy are a dynamic clinical entity with significant implications for maternal and fetal health. Advances in understanding pathophysiology, risk stratification, and management have improved outcomes, yet challenges persist, particularly in resource-limited settings. Clinicians must remain vigilant in screening, diagnosing, and managing HDP, applying evidence-based guidelines and emerging therapies where appropriate. Ongoing research into biomarkers, prevention strategies, and individualized therapies holds promise for further reducing the global burden of HDP and enhancing long-term health for affected women and their children.